RecruitingNot Applicable

Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces

China500 participantsStarted 2025-06-01

Plain-language summary

The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
. Patients who have undergone surgical lung resection;
. Patients with complete preoperative chest CT imaging data;
. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.

Exclusion criteria

. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubé \[BHD\] syndrome);
. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

DFS

Timeframe: From enrollment to the end of surgery for 5 years

Trial details

NCT IDNCT07066813

SponsorCentral South University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-31

Contact for this trial

Chen Chen

+8673185295188 chenchen1981412@csu.edu.cn

View on ClinicalTrials.gov More Lung Cancer Associated With Cystic Airspaces trials